MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1726 48 mg Cohort Study Extended to Eight Weeks On August 6, 2025, ...

In a groundbreaking study, scientists have identified a gut microbe, Bacteroides vulgatus, and its metabolites as potential ...

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

Eli Lilly has launched pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving more options for those ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

The pen will be available in six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing healthcare ...

In India, home to 74 million diabetes patients, a range of supplements is being marketed as natural GLP-1 alternatives, but ...

This occurred as the drug major Emcure Pharmaceuticals presented bioequivalence study report along with the Phase-III ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients ...

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.